Paclitaxel as first or second-line treatment for HIV-negative Kaposi's sarcoma: a retrospective study of 58 patients.

CONCLUSION: Paclitaxel is effective for the treatment of non-HIV related KS, both as first or second-line treatment. It is well tolerated and can be repeated without loss of efficacy. PMID: 30897011 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research